Total Payments
$44,094
2024 Payments
$723.77
Companies
15
Transactions
110
Medicare Patients
356
Medicare Billing
$66,757
Payment Breakdown by Category
Consulting$23,683 (53.7%)
Other$10,450 (23.7%)
Travel$5,013 (11.4%)
Food & Beverage$4,683 (10.6%)
Education$264.75 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $23,683 | 11 | 53.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,600 | 6 | 17.2% |
| Travel and Lodging | $5,013 | 17 | 11.4% |
| Food and Beverage | $4,683 | 69 | 10.6% |
| Honoraria | $2,350 | 2 | 5.3% |
| Charitable Contribution | $500.00 | 1 | 1.1% |
| Education | $264.75 | 4 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $28,122 | 62 | $0 (2022) |
| PFIZER INC. | $7,268 | 8 | $0 (2024) |
| Janssen Biotech, Inc. | $3,787 | 21 | $0 (2024) |
| Seagen Inc. | $1,999 | 3 | $0 (2022) |
| Aveo Pharmaceuticals, Inc. | $1,500 | 1 | $0 (2021) |
| Bristol-Myers Squibb Company | $709.50 | 1 | $0 (2019) |
| Genentech USA, Inc. | $231.49 | 3 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $112.32 | 1 | $0 (2018) |
| Seattle Genetics, Inc. | $104.15 | 1 | $0 (2019) |
| Janssen Products, LP | $85.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $723.77 | 13 | Janssen Biotech, Inc. ($349.91) |
| 2023 | $326.51 | 10 | Janssen Biotech, Inc. ($272.40) |
| 2022 | $2,991 | 4 | AstraZeneca Pharmaceuticals LP ($2,740) |
| 2021 | $1,500 | 1 | Aveo Pharmaceuticals, Inc. ($1,500) |
| 2020 | $3,360 | 4 | Seagen Inc. ($1,860) |
| 2019 | $10,981 | 21 | PFIZER INC. ($5,486) |
| 2018 | $9,671 | 22 | AstraZeneca Pharmaceuticals LP ($9,474) |
| 2017 | $14,541 | 35 | AstraZeneca Pharmaceuticals LP ($14,440) |
All Payment Transactions
110 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/28/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $34.61 | General |
| Category: Immunology | ||||||
| 09/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), BALVERSA, AKEEGA | Food and Beverage | In-kind items and services | $33.42 | General |
| Category: Oncology | ||||||
| 08/24/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), BALVERSA, AKEEGA | Food and Beverage | In-kind items and services | $26.87 | General |
| Category: Oncology | ||||||
| 07/23/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: ONCOLOGY | ||||||
| 06/25/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 06/24/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Education | In-kind items and services | $74.99 | General |
| Category: Oncology | ||||||
| 06/03/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 05/17/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $27.20 | General |
| Category: Oncology | ||||||
| 05/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.42 | General |
| 04/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.42 | General |
| 02/14/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $28.50 | General |
| Category: Oncology | ||||||
| 01/27/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $147.59 | General |
| Category: ONCOLOGY | ||||||
| 01/26/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $124.32 | General |
| Category: Oncology | ||||||
| 12/06/2023 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: Oncology | ||||||
| 12/06/2023 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $10.41 | General |
| Category: Oncology | ||||||
| 11/21/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $13.09 | General |
| Category: Oncology | ||||||
| 11/17/2023 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $30.32 | General |
| Category: Oncology | ||||||
| 11/02/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $29.63 | General |
| Category: Oncology | ||||||
| 10/05/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $38.61 | General |
| Category: Oncology | ||||||
| 09/20/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: Oncology | ||||||
| 09/06/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $21.21 | General |
| Category: Oncology | ||||||
| 06/02/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $127.18 | General |
| Category: Oncology | ||||||
| 03/28/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $19.81 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 06/06/2022 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $113.08 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 72 | 169 | $87,445 | $18,806 |
| 2022 | 5 | 116 | 196 | $89,396 | $21,654 |
| 2021 | 6 | 116 | 169 | $64,079 | $18,130 |
| 2020 | 3 | 52 | 88 | $38,897 | $8,168 |
Total Patients
356
Total Services
622
Medicare Billing
$66,757
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 45 | 141 | $75,569 | $15,653 | 20.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 15 | 15 | $8,430 | $2,194 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 13 | $3,446 | $958.43 | 27.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 40 | 111 | $57,054 | $12,446 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 31 | 39 | $9,943 | $3,020 | 30.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 19 | $11,220 | $2,964 | 26.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $8,112 | $2,264 | 27.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 12 | 12 | $3,067 | $959.89 | 31.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 26 | 45 | $22,275 | $5,274 | 23.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 27 | 42 | $10,362 | $3,378 | 32.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 20 | $10,825 | $3,284 | 30.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 33 | $9,339 | $2,744 | 29.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 15 | $7,818 | $2,293 | 29.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 11 | 14 | $3,460 | $1,157 | 33.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 24 | 55 | $26,317 | $5,007 | 19.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 14 | 14 | $8,090 | $1,913 | 23.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 14 | 19 | $4,490 | $1,248 | 27.8% |
About Dr. Jianjun Gao, M.D
Dr. Jianjun Gao, M.D is a Medical Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053356873.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jianjun Gao, M.D has received a total of $44,094 in payments from pharmaceutical and medical device companies, with $723.77 received in 2024. These payments were reported across 110 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($23,683).
As a Medicare-enrolled provider, Gao has provided services to 356 Medicare beneficiaries, totaling 622 services with total Medicare billing of $66,757. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Houston, TX
- Active Since 06/17/2006
- Last Updated 11/13/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1053356873
Products in Payments
- IMFINZI (Drug) $24,737
- BAVENCIO (Drug) $4,506
- Balversa (Drug) $2,877
- IMFINZI (Biological) $2,740
- PADCEV (Biological) $2,021
- FOTIVDA (Drug) $1,500
- INLYTA (Drug) $1,477
- ERLEADA (Drug) $699.94
- Erleada (Drug) $287.27
- TECENTRIQ (Biological) $131.49
- ZYTIGA (Drug) $85.00
- CABOMETYX (Drug) $44.75
- TREMFYA (Drug) $34.61
- RYDAPT (Drug) $30.85
- LYNPARZA (Biological) $24.89
- KEYTRUDA (Biological) $19.81
- Lenvima (Drug) $13.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Houston
Roy Herbst, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Putao Cen, Md, MD
Medical Oncology — Payments: $817,580
Medical Oncology $817,580
Hagop Kantarjian, Md, MD
Medical Oncology — Payments: $740,835
Medical Oncology $740,835
Dr. Matthew Ellis, Md Phd, MD PHD
Medical Oncology — Payments: $714,994
Medical Oncology $714,994
Eleni Efstathiou, M.d, M.D
Medical Oncology — Payments: $600,908
Medical Oncology $600,908
Srdan Verstovsek, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $577,763
Medical Oncology $577,763